Search clinical trials for: Spiriva (tiotropium bromide 18ug)

Total 375 results

Duke University

Withdrawn

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

Chronic Obstructive Pulmonary Disease (COPD)
McMaster University
Boehringer Ingelheim

Completed

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

COPD
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Pulmonary Disease, Chronic Obstructive
University of Saskatchewan

Completed

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Allergic Asthma

Canada
Phargentis SA

Completed

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

COPD

United States, India, Switzerland
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Cystic Fibrosis
3M
Quotient Clinical

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products

Healthy

United Kingdom
University of Milan
Fondazione Salvatore Maugeri

Completed

Closing Volume Interpretation and Bronchodilators Effect

Healthy | COPD

Italy
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
Lupin, Inc.

Completed

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Chronic Obstructive Pulmonary Disease, COPD

Sweden, France, Germany, Hungary, Poland, Canada, Australia, Slovakia, Spain
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Boehringer Ingelheim
Pfizer

Completed

Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.

Asthma

Austria, Germany, Ukraine
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
Boehringer Ingelheim
Pfizer

Completed

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Asthma

United States, Germany, Latvia, Lithuania, Slovenia
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler (TIOPIF)

Healthy Volunteer | COPD

Estonia
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Romania, Poland, Czechia
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Healthy
AstraZeneca

Completed

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Guangzhou Institute of Respiratory Disease
Boehringer Ingelheim

Recruiting

Effect of Tiotropium Bromide Combined With Odaterol on Small Airway Remodeling in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

Healthy
Boehringer Ingelheim

Completed

Specific Use-Result of Spiriva Respimat® in Asthmatics

Asthma

Japan
Boehringer Ingelheim

Completed

Early Intervention Efficacy in COPD

Pulmonary Disease, Chronic Obstructive

Japan
Radboud University Medical Center

Completed

Interaction in Chronic Obstructive Pulmonary Disease Experiment (ICE)

Smoking | Cardiovascular Disease | Chronic Obstructive Pulmonary Disease | Bronchodilation

Netherlands
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler

Healthy Subjects

Finland
Boehringer Ingelheim

Completed

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Italy
Boehringer Ingelheim

Completed

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

Pulmonary Disease, Chronic Obstructive

Germany
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Boehringer Ingelheim

Completed

RUSSE / Russian Spiriva® Safety & Efficacy Study

COPD

Russian Federation
Mylan Inc.
Theravance Biopharma

Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD | Low Peak Inspiratory Flow Rate (PIFR)

United States
University of Saskatchewan

Completed

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma

Asthma

Canada
Laval University
Boehringer Ingelheim

Completed

Effects of Tiotropium on Walking Capacity in Patients With COPD

Chronic Obstructive Pulmonary Disease

Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (EMERALD2)

COPD

Mexico
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Spiriva® Assessment of FEV1 (SAFE)

Pulmonary Disease, Chronic Obstructive

Canada
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom

3

Subscribe